Skip to main content

Table 3 Sensitivity analysis and reference levels of inputs

From: The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models

Name

Initial efficacy a

Half-life a

Decay shape a

Vaccine coverage

Reference

EPI: 62.5 %, 6-9 months: 79.2 %

EPI : 1.12 year, 6-9 months: 1.12 year

Exponential

EPI: DTP3, 6-9 months: 75 % of DTP3

B

Reference

Reference

Reference

Increase 6-9 months to EPI coverage

C

Increase (EPI: 80.3 %, 6-9 months: 84.8 %)

Reference

Reference

Reference

D

Decrease (EPI: 39.5 %, 6-9 months: 67.3. %)

Reference

Reference

Reference

E

Reference

Increase (EPI : 3 year, 6-9 months: 3 year)

Reference

Reference

F

Decrease (EPI: 39.5 %, 6-9 months: 67.3. %)

Increase (EPI : 3 year, 6-9 months: 3 year)

Reference

Reference

G

Increase (EPI: 80.3 %, 6-9 months: 84.8 %)

Increase (EPI : 3 year, 6-9 months: 3 year)

Reference

Reference

  1. aVaccine efficacy against infection and vaccine half-life of decay against infection